A Milestone in Type 1 Diabetes Treatment
A 25-year-old woman from northern China spent the last ten years relying on daily insulin injections to manage her Type 1 diabetes. In a groundbreaking event during the summer of 2023, she received a unique treatment that, according to recorded history, is the first known case to restore natural insulin production using cells from her own body. The implications of this achievement from the Deng laboratory are immense, particularly when considering the century-long challenge of treating Type 1 diabetes. This autoimmune condition causes the immune system to destroy insulin-producing beta cells in the pancreas, usually occurring in childhood or adolescence without warning. Traditionally, there’s been no way to recover these damaged cells. Since the landmark discovery of insulin by Frederick Banting and Charles Best in 1921, the standard course of treatment has involved multiple daily insulin injections, regular glucose monitoring, careful diet planning, and lifelong management of the condition. Currently, about 9 million people around the globe follow this routine.
Addressing Type 1 diabetes with cell-based therapies poses significant challenges. Firstly, there’s the issue of sourcing enough functional insulin-producing islet cells to replace those that have been destroyed. Secondly, there’s the need to safeguard these replacement cells from the very immune system that previously targeted the original cells. The Edmonton Protocol, created in 2000 at the University of Alberta, partially tackled the first challenge by showing that islet cells could be harvested from deceased donors and transplanted into diabetes patients, leading to temporary improvements in insulin production. However, this method still required lifelong immunosuppression to prevent the body from rejecting the foreign cells, and donor cells were not available in sufficient quantities for widespread treatment.
The Method Behind Deng’s Breakthrough
The team at Peking University took an innovative approach by using the patient’s own cells for the transplant. They obtained a small sample of fat tissue from her abdomen, which is a common outpatient procedure. The researchers then chemically reprogrammed these fat cells back into pluripotent stem cells, allowing them to regain the ability to grow into various tissue types. Their method, known as chemically induced pluripotent stem cells (CiPSCs), is different from a technique developed by Japanese scientist Shinya Yamanaka in 2006, which relies on introducing specific genes into the cells’ DNA. The chemical approach is regarded as having a lower risk of potential mutations and tumors compared to genetic methods.
Over several months, the CiPSCs were then transformed into functional pancreatic islet cells capable of producing insulin in response to rising blood glucose levels. After verifying their functionality, around 1.5 million of these cells were transplanted in June 2023 to a novel site for islet transplantation—this allowed for easier post-transplant monitoring. The surgery lasted about 30 minutes, and the patient recovered smoothly. Within two weeks, her insulin needs began to drop, and in about 75 days, she stopped using external insulin altogether. Her hemoglobin A1c levels, a critical measure of blood sugar control, improved significantly, showing that her time spent within a healthy glucose range soared from about 43% before the treatment to over 98% afterward.
What Remains Unclear
Despite this promising development, the results from the Deng laboratory come with some important limitations. The most notable is that this was a single case, meaning the findings can’t be readily generalized to all Type 1 diabetes patients without further extensive clinical trials. Though two additional patients have joined the study and preliminary findings are positive, peer-reviewed results are still pending. Another consideration is that the patient had previously undergone a liver transplant for an unrelated health issue, so she was already on immunosuppressive medication when she received the islet cells. This raises questions about whether autologous cells would also survive without such medication since they should ideally be recognized as part of the body’s own system.
Lastly, there’s the question of how long the effectiveness of this treatment will last. The one-year follow-up included in the published results is positive but shorter than what’s typically seen with previous transplant methods, which often lead to a gradual loss of function over several years. The hope is that these autologous, chemically reprogrammed islets might be more enduring. Hongkui Deng, the lead researcher, has clarified that this is not a definitive cure for Type 1 diabetes and that much more research is needed before considering it for broader application. While the results from this trial are groundbreaking, they currently represent a concept rather than an established medical procedure. Importantly, for the first time, a patient has lived without insulin injections for over a year since her diagnosis in 2012, highlighting the potential of this innovative approach.
